Bristol Myers Wins Positive Opinion From EU For Opdivo/Yervoy Combo In Colorectal Cancer

by Vandana Singh, Benzinga Editor
May 24, 2021 8:21 AM | 27 seconds read |
  • The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Bristol Myers Squibb & Co's BMY Opdivo (nivolumab) in combination with Yervoy (ipilimumab), a subset of metastatic colorectal cancer (mCRC).
  • The recommendation covers the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) mCRC after prior fluoropyrimidine-based combination chemotherapy.
  • The opinion was based on data from the Phase 2 CheckMate -142 trial.
  • Price Action: BMY shares closed at $67.05 on Friday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In:
BiotechNewsHealth CareFDAGeneralBriefscolorectal cancereuropean medical agency
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved